5-Fraction SBRT Noninferior to Conventional XRT for Low-, Intermediate-Risk PC

Background: Prostate cancer (PC) is one of the bread-and-butter cancers that radiation oncologists treat. Economically, it could not be more important. With increasing precision, radiation oncologists can spare more normal tissue and, therefore, patients can tolerate higher doses per fraction while maintaining efficacy. PC cells grow slower than some surrounding normal tissue, so hypofractionation may improve efficacy. PACE (Prostate Advances in Comparative Evidence) is a platform of studies designed to evaluate the safety and efficacy of 5-fraction stereotactic body radiotherapy (SBRT). PACE-A compares SBRT with surgery. PACE-B and PACE-C compare SBRT with conventional or moderately hypofractionated radiotherapy (XRT). PACE-B includes low- and intermediate-risk disease. PACE-C is for higher-risk patients receiving ADT. This report is on PACE-B. Objective: To assess the noninferiority of 5-fraction SBRT compared to moderately hypofractionated XRT with regard to biochemical or clinica more...